SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: David Bogdanoff who wrote (10666)11/3/1997 9:42:00 AM
From: Henry Niman  Respond to of 32384
 
David, CNBC said a "handfull" of patients had experienced the problem, but didn't go farther. Merrill Lynch says BMY, maker of Glucophage may benefit. LGND has moved up to $15.



To: David Bogdanoff who wrote (10666)11/3/1997 9:58:00 AM
From: Henry Niman  Respond to of 32384
 
Merrill downgraded WLA both near and long term. Reuter's reports a label change for Rezulin. WLA expected to open at about $136.